- About SARC
- About Sarcoma
- Patient Resources
- SARC Trials
- Support Sarcoma Research
Chairman of the Board, McHenry "Mac" Tichenor.
Mac Tichenor, has a long record of running successful organizations. His original interactions with SARC relates to his position as Executive Director of the WWWW Foundation, Inc.
The WWWW Foundation (QuadW) was established in memory of Mac’s son Willie Tichenor, who died of osteosarcoma in 2006 at age 19. Its name stands for “What Would Willie Want?” and that standard informs the Foundation’s work. The Foundation supports innovative ideas in higher education, sarcoma research, personally transforming mission experiences, and general philanthropy. Seven of Willie’s close friends comprise the Foundation’s advisory board, contributing fresh outlooks and ideas while learning the practice of philanthropy. The Foundation has sought to advance projects that can broadly facilitate research in sarcoma. In addition to its work in cancer research, the Foundation has funded numerous college programs and scholarships, as well as mission opportunities. The Foundation has made valuable contributions to SARC's unified database project.
Mac Tichenor earned a Bachelor of Arts degree with Honors in Plan II, with a concentration in economics from the University of Texas at Austin in 1977, followed by an MBA from UT Austin, along with the Dean's Award for Academic Excellence. Mac Tichenor began a career in broadcasting in 1979 when he joined Tichenor Media System, a third-generation, family-owned company based in Harlingen, Texas. In 1981, Mac became president of Tichenor Media and oversaw its expansion into Spanish-language radio. In 1997, the company merged with Hispanic Broadcasting Corporation, creating the largest Hispanic radio company in the U.S., and Mac was named Chairman, President and CEO of the company. In 2003, Hispanic Broadcasting merged with Univision Communications Inc., the largest diversified Spanish-language media company in the United States. Mac joined the Univision’s board of directors, and was President of the company’s radio division.
Mac eventually left day-to-day operations of Univision Radio and earned a Masters of Science in Biotechnology at the University of Texas at Dallas in 2009. In 2010, he formed Tichenor Ventures, LLC as a private biotechnology investment vehicle.
Mac Tichenor's other accomplishments include his current position as a director of Belo Corp (NYSE: BLC) and NGM Biopharmaceuticals, Inc. and his former position as director of HFF Inc. (NYSE: HF), and 8e6 Technologies. He is active on various boards of the University of Texas at Austin, including the Advisory Council of the McCombs School of Business, and is a Member of the MD Anderson Cancer Center Board of Visitors. Other civic involvement has included serving as Chairman of the Harlingen Area United Way Campaign, Chairman of the Harlingen Area Chamber of Commerce, board member of the Gladys Porter Zoo of Brownsville, Chairman of the Texas Business Hall of Fame, and a member of the Texas Lyceum. He has served as a director of the Texas Association of Broadcasters and the National Association of Broadcasters, and is a member of the World Presidents’ Organization. Honors include recognition as a distinguished alumnus of the UT Austin business school (1987), being named Texas Association of Broadcasters Broadcaster of the Year (2001), and induction into the Texas Radio Hall of Fame (2003). In 2005, along with his grandfather, father and brother Warren, he was named one of the Library of American Broadcasting’s “Giants of Broadcasting,” and received the National Association of Broadcasting’s Pioneer Broadcaster award in 2006. In 2008, he was named to the McCombs School of Business Hall of Fame.
Mac and his wife Lisa reside in Dallas, Texas, and are active in the Highland Park United Methodist Church. They have a son, Taylor, who lives and works in Dallas. Mac’s hobbies include music, skiing, bicycling, hiking, and flying.
We welcome Mac Tichenor as SARC’s Chairman of the Board. We look forward to his business expertise in our future collaborations in bringing the most innovative treatments to patients as quickly as possible.